Patisiran prevents functional decline in patients with cardiac amyloidosis
1. In this randomized controlled trial, patisiran demonstrated a reduction in functional capacity decline transthyretin amyloidosis (ATTR amyloidosis) with a ...
Tag: Patisiran
#VisualAbstract: Patisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis
Click here to read this study in NEJM. ©2023 2 Minute Medicine, Inc. All rights reserved. No works may be ...
Patisiran therapy reduces ventricular myocardial strain in hereditary transthyretin amyloidosis
1. Use of patisiran, an RNA interference therapy, in patients with hereditary transthyretin (hATTR) cardiac amyloidosis was linked to reduced ...
Patisiran is effective in treatment of hereditary transthyretin amyloidosis.
1. Patisiran, an RNA interference agent, improved neuropathy symptoms and motor function in patients with hereditary transthyretin amyloidosis after 18 ...